Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors?

Research output: Contribution to journalArticle

Abstract

Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.

Original languageEnglish
Pages (from-to)9-31
Number of pages23
JournalJournal of OncoPathology
Volume2
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Gastrointestinal Stromal Tumors
Neuroendocrine Tumors
Neoplasms
Cell Lineage
Somatostatin
Terminology
Gastrointestinal Tract
Pathologists
Differential Diagnosis
Therapeutics

Keywords

  • CD117
  • Cdx-2 GIST
  • Isl-1
  • KIT
  • NET
  • Neuroendocrine tumor
  • PDGFRA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pathology and Forensic Medicine

Cite this

Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors? / Milione, Massimo; Pilotti, Silvana; Pelosi, Giuseppe.

In: Journal of OncoPathology, Vol. 2, No. 3, 2014, p. 9-31.

Research output: Contribution to journalArticle

@article{49fb6822d33e4c70ba37eb9caabcfdb5,
title = "Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors?",
abstract = "Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.",
keywords = "CD117, Cdx-2 GIST, Isl-1, KIT, NET, Neuroendocrine tumor, PDGFRA",
author = "Massimo Milione and Silvana Pilotti and Giuseppe Pelosi",
year = "2014",
doi = "10.13032/tjop.2052-5931.100094",
language = "English",
volume = "2",
pages = "9--31",
journal = "Journal of OncoPathology",
issn = "2052-5931",
publisher = "Good Health Trading Limited",
number = "3",

}

TY - JOUR

T1 - Is the pathologist indispensable in gastrointestinal stromal tumors and neuroendocrine tumors?

AU - Milione, Massimo

AU - Pilotti, Silvana

AU - Pelosi, Giuseppe

PY - 2014

Y1 - 2014

N2 - Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.

AB - Neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs) are different tumor categories with no pathogenetic, morphologic, clinical, or therapeutic similarities: NETs are epithelial to neural tumors in contrast to GISTs, which show mesenchymal cell lineage. Both tumors, however, arise more frequently from the gastrointestinal tract and may benefit of specific target therapeutic approaches: imatinib/STI-571 for GISTs and m-Tor pathway inhibitors or somatostatin analogs for NETs. The role of pathologist is crucial when dealing with both NETs and GISTs, as morphological, immunohistochemical, and molecular analysis often provide helpful information on the clinical behavior and management. We here propose a general overview on nomenclature of tumors classification and suggestions for histological report of both NETs and GISTs. Moreover, we will approach in finer details the immunohistochemical analysis on origin and differential diagnosis in NETs as well as the prognosis and resistance to therapy in GISTs. This review emphasized recent literature advances regarding similarities and differences in the managerial pathologist's approach to either tumor type.

KW - CD117

KW - Cdx-2 GIST

KW - Isl-1

KW - KIT

KW - NET

KW - Neuroendocrine tumor

KW - PDGFRA

UR - http://www.scopus.com/inward/record.url?scp=84906982772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906982772&partnerID=8YFLogxK

U2 - 10.13032/tjop.2052-5931.100094

DO - 10.13032/tjop.2052-5931.100094

M3 - Article

VL - 2

SP - 9

EP - 31

JO - Journal of OncoPathology

JF - Journal of OncoPathology

SN - 2052-5931

IS - 3

ER -